Hefei Hengxin Life Science and Technology Co., Ltd. (SHE:301501)
China · Delayed Price · Currency is CNY 42.54
-0.25 (-0.58%)
Feb 13, 2026, 3:04 PM CST
SHE:301501 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,788 | 1,562 | 1,396 | 1,054 | 696.15 | 415.09 |
Other Revenue | 32.16 | 32.16 | 29.51 | 33.89 | 22.75 | 9.36 |
| 1,820 | 1,594 | 1,425 | 1,088 | 718.9 | 424.44 | |
Revenue Growth (YoY) | 27.71% | 11.87% | 30.95% | 51.38% | 69.37% | -22.03% |
Cost of Revenue | 1,378 | 1,178 | 1,023 | 786.93 | 524.89 | 286.38 |
Gross Profit | 441.85 | 416.43 | 401.63 | 301.34 | 194.01 | 138.06 |
Selling, General & Admin | 124.86 | 100.28 | 93.46 | 70.71 | 51.85 | 72.56 |
Research & Development | 54.64 | 53.31 | 44.21 | 35.91 | 32.15 | 19.62 |
Other Operating Expenses | 6.49 | 6.93 | 6.04 | 4.29 | 4.23 | 3.24 |
Operating Expenses | 186.92 | 161.4 | 146.94 | 113.04 | 88.65 | 95.25 |
Operating Income | 254.94 | 255.03 | 254.69 | 188.3 | 105.36 | 42.81 |
Interest Expense | -9.76 | -10.03 | -5.31 | -4.41 | -2.62 | -2.09 |
Interest & Investment Income | 4.71 | 2.35 | 3.01 | 1.66 | 1.03 | 2.05 |
Earnings From Equity Investments | -0 | -0 | - | - | - | - |
Currency Exchange Gain (Loss) | -5.91 | -5.91 | 3.65 | 7.03 | -2.4 | -3.87 |
Other Non Operating Income (Expenses) | 47.9 | 11.38 | -0.39 | -0.33 | -0.26 | -1.24 |
EBT Excluding Unusual Items | 291.88 | 252.82 | 255.65 | 192.25 | 101.11 | 37.66 |
Gain (Loss) on Sale of Investments | 2.17 | - | -2.14 | -5.5 | -11.29 | -8.1 |
Gain (Loss) on Sale of Assets | 0.31 | 0.88 | -0.3 | 0.24 | 0.05 | - |
Asset Writedown | -1.89 | -0.51 | -2.41 | -1.17 | -0.01 | -0.25 |
Other Unusual Items | 8.04 | 8.04 | 7.2 | 6.08 | 4.08 | 6.15 |
Pretax Income | 300.52 | 261.24 | 258.01 | 191.91 | 93.94 | 35.45 |
Income Tax Expense | 45.84 | 34.43 | 36.56 | 25.95 | 12.86 | 10.58 |
Earnings From Continuing Operations | 254.68 | 226.81 | 221.46 | 165.95 | 81.08 | 24.88 |
Minority Interest in Earnings | -11.91 | -6.92 | -7.59 | -3.19 | -0.92 | 1.21 |
Net Income | 242.77 | 219.89 | 213.86 | 162.77 | 80.16 | 26.09 |
Net Income to Common | 242.77 | 219.89 | 213.86 | 162.77 | 80.16 | 26.09 |
Net Income Growth | 13.52% | 2.82% | 31.39% | 103.04% | 207.30% | -62.87% |
Shares Outstanding (Basic) | 132 | 111 | 111 | 111 | 105 | - |
Shares Outstanding (Diluted) | 132 | 111 | 111 | 111 | 105 | - |
Shares Change (YoY) | 19.59% | 0.31% | -0.04% | 5.81% | - | - |
EPS (Basic) | 1.83 | 1.98 | 1.93 | 1.47 | 0.77 | - |
EPS (Diluted) | 1.83 | 1.98 | 1.93 | 1.47 | 0.77 | - |
EPS Growth | -5.08% | 2.50% | 31.45% | 91.90% | - | - |
Free Cash Flow | -103.79 | -78.83 | -110.86 | 2.58 | 9.75 | -27.11 |
Free Cash Flow Per Share | -0.78 | -0.71 | -1.00 | 0.02 | 0.09 | - |
Dividend Per Share | 0.345 | 0.345 | - | - | - | - |
Gross Margin | 24.28% | 26.12% | 28.18% | 27.69% | 26.99% | 32.53% |
Operating Margin | 14.01% | 16.00% | 17.87% | 17.30% | 14.66% | 10.09% |
Profit Margin | 13.34% | 13.79% | 15.01% | 14.96% | 11.15% | 6.15% |
Free Cash Flow Margin | -5.70% | -4.95% | -7.78% | 0.24% | 1.36% | -6.39% |
EBITDA | 340.96 | 322.51 | 297.44 | 221.74 | 129.15 | 62.83 |
EBITDA Margin | 18.73% | 20.23% | 20.87% | 20.38% | 17.96% | 14.80% |
D&A For EBITDA | 86.02 | 67.48 | 42.75 | 33.43 | 23.79 | 20.02 |
EBIT | 254.94 | 255.03 | 254.69 | 188.3 | 105.36 | 42.81 |
EBIT Margin | 14.01% | 16.00% | 17.87% | 17.30% | 14.66% | 10.09% |
Effective Tax Rate | 15.25% | 13.18% | 14.17% | 13.52% | 13.69% | 29.83% |
Revenue as Reported | 1,820 | 1,594 | 1,425 | 1,088 | 718.9 | 424.44 |
Advertising Expenses | - | - | 2 | 0.55 | 1.16 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.